Relay Therapeutics, Inc. $RLAY Shares Purchased by Janus Henderson Group PLC

Janus Henderson Group PLC raised its position in Relay Therapeutics, Inc. (NASDAQ:RLAY) by 77.8% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 65,573 shares of the company’s stock after purchasing an additional 28,700 shares during the period. Janus Henderson Group PLC’s holdings in Relay Therapeutics were worth $652,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of RLAY. Torren Management LLC acquired a new stake in shares of Relay Therapeutics in the fourth quarter valued at about $30,000. KBC Group NV acquired a new position in Relay Therapeutics during the first quarter worth about $34,000. Smartleaf Asset Management LLC boosted its position in Relay Therapeutics by 288.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock worth $37,000 after acquiring an additional 3,287 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Relay Therapeutics during the 4th quarter valued at about $46,000. Finally, Captrust Financial Advisors purchased a new stake in Relay Therapeutics during the 2nd quarter valued at about $49,000. Hedge funds and other institutional investors own 96.98% of the company’s stock.

Relay Therapeutics Stock Up 0.9%

NASDAQ:RLAY opened at $19.94 on Tuesday. The stock’s fifty day moving average is $17.83 and its two-hundred day moving average is $13.61. Relay Therapeutics, Inc. has a 52 week low of $3.15 and a 52 week high of $20.79. The stock has a market capitalization of $4.37 billion, a price-to-earnings ratio of -12.70 and a beta of 1.69.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). The firm had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.96 million. On average, sell-side analysts expect that Relay Therapeutics, Inc. will post -1.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on RLAY shares. Guggenheim reissued a “buy” rating on shares of Relay Therapeutics in a research note on Friday. Oppenheimer boosted their target price on shares of Relay Therapeutics from $14.00 to $18.00 and gave the company an “outperform” rating in a report on Tuesday, April 28th. HC Wainwright raised their price target on shares of Relay Therapeutics from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. UBS Group set a $26.00 price objective on Relay Therapeutics in a report on Tuesday, May 19th. Finally, Citizens Jmp raised their target price on Relay Therapeutics from $21.00 to $26.00 and gave the stock a “market outperform” rating in a research note on Monday. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $25.58.

Insider Buying and Selling at Relay Therapeutics

In other news, CFO Thomas Catinazzo sold 1,459 shares of the stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $18.61, for a total transaction of $27,151.99. Following the sale, the chief financial officer owned 158,285 shares of the company’s stock, valued at approximately $2,945,683.85. This represents a 0.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sanjiv Patel sold 48,199 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $19.58, for a total transaction of $943,736.42. Following the completion of the transaction, the chief executive officer directly owned 615,898 shares of the company’s stock, valued at approximately $12,059,282.84. The trade was a 7.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 427,356 shares of company stock valued at $7,461,240 over the last three months. 5.04% of the stock is currently owned by company insiders.

Relay Therapeutics Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.